January 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable electronic injector designed to enhance the administration of injectable medications while helping partners meet their sustainability goals.
Cambridge, MA. - January 7, 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable injector designed to enhance the administration of injectable medications. Built on Portal’s robust platform technology, the PRIME Nexus is a needle-based device designed to be compatible with standard primary containers, including 1mL pre-filled syringes (PFS), 2.25mL PFS, and 3mL cartridges.
The PRIME Nexus represents a significant advancement in drug delivery, offering precise control and versatility for a wide range of therapies. This innovative device is poised to be a game-changer for pharmaceutical companies and patients alike, offering several key advantages:
The PRIME Nexus is designed to seamlessly integrate into existing manufacturing and packaging processes, streamlining the development and commercialization of new injectable therapies. Its compatibility with standard primary containers further simplifies integration and reduces development timelines.
Portal Instruments will showcase the PRIME Nexus device at Pharmapack and other key industry events. Attendees will have the opportunity to see the device in action and discuss feasibility or development studies for this reusable injector.
About Portal Instruments:
Portal Instruments is a privately held medical device company focused on developing and commercializing innovative drug delivery platform technologies to transform the administration of injectable medications. Portal's goal is to improve patient experience, adherence, and outcomes by providing advanced delivery solutions.
Portal Instruments is pleased to be showcasing its latest drug delivery platform at the LSI conference in California next week. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact.
February 11, 2020 - Gerresheimer recently published an article describing Portal Instrument’s innovative primary drug container which is used in Portal’s needle-free drug delivery platform. Read the full pdf article here.
March 23, 2021 - Cambridge, MA The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership. Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with NMOSD.
Please fill out the details below and we will get back to you shortly.